证券代码：300633 证券简称：开立医疗 公告编号：2025-044 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 深圳开立生物医疗科技股份有限公司（以下简称"公司"）2025 年限制性 股票与股票期权激励计划（以下简称"《激励计划》"或"本次激励计划"）规定 的授予条件已经成就，根据公司2025年第一次临时股东大会的授权，公司于2025 年 10 月 16 日召开了第四届董事会第十一次会议和第四届监事会第十次会议， 审议通过《关于调整 2025 年限制性股票与股票期权激励计划激励对象名单相关 事项的议案》、《关于向 2025 年限制性股票与股票期权激励计划激励对象授予限 制性股票与股票期权的议案》，确定以 2025 年 10 月 16 日为第二类限制性股票 授予日和股票期权授权日，向 99 名激励对象授予 191.4 万股第二类限制性股票， 向 306 名激励对象授予 396.78 万份股票期权。具体如下： 深圳开立生物医疗科技股份有限公司 关于向 2025 年限制性股票与股票期权激励计划激励对象授予限 制性股票与股票期权的公告 一、本次 ...

深圳开立生物医疗科技股份有限公司（以下简称"公司"）第四届监事会第 十次会议于 2025 年 10 月 16 日在公司会议室召开，审议通过了《关于调整 2025 年限制性股票与股票期权激励计划激励对象名单相关事项的议案》、《关于向 2025 年限制性股票与股票期权激励计划激励对象授予限制性股票与股票期权的 议案》。公司监事会根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、《深圳证券交易所创业板股票上市规则》（以下简称 "《上市规则》"）等相关法律、法规和规范性文件以及公司《2025 年限制性股票 与股票期权激励计划（草案）》（以下简称"《激励计划》"或"本次激励计划"）、 《公司章程》的有关规定，对公司 2025 年限制性股票与股票期权激励计划激励对 象名单（授予日）进行审核，发表核查意见如下： （一）鉴于公司《2025 年限制性股票与股票期权激励计划（草案）》（以下简 称"《激励计划》"或"本次激励计划"）确定的激励对象名单中，1 名激励对象 因个人原因自愿放弃参与本次激励计划，根据公司 ...

注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票均未 超过公司总股本的 1%。公司全部有效期内的激励计划所涉及的标的股票总数累计不超过股权激 励计划提交股东会审议时公司股本总额的 20%。 2、本激励计划拟授予激励对象不包括独立董事、监事、外籍员工、单独或合计持有公司 5% 以上股份的股东及公司实际控制人的配偶、父母、子女。 3、上表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致。 | 序号 姓名 | | 国籍 | 职务 | 获授股票期 权份额（万 | 占本激励计划 授予股票期权 | 占目前总股本的 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 份） | 总数的比例 | 比例 | | 1 | / | / | / | / | / | / | | 中层管理人员和技术业务骨干（共 | | | 人） 306 | 396.78 | 100.00% | 0.92% | | 合计 | | | | 396.78 | 100.00% | 0.92% | 二、股票期权分配情况 深圳开立生物医疗科技股份有限公司 2025 ...

Investment Rating - Industry investment rating is "Outperform the Market" (expected to outperform the CSI 300 index by more than 5% in the next 6 months) [2][24] Core Insights - The bidding environment for medical equipment remains robust, with strong demand for procurement in county-level medical communities driven by ongoing equipment update policies since 2025 [4][22] - The procurement scale for medical devices has maintained a high level, with notable monthly figures in July, August, and September 2025 being 12.8 billion, 13.1 billion, and 12.7 billion respectively, showing year-on-year growth rates of +21%, +18%, and -21% [4][13] - Major companies are benefiting significantly from the recovery in equipment update bidding, with procurement figures for September showing ultrasound at 1.646 billion (yoy +30%), CT at 1.717 billion (yoy +29%), and MRI at 1.512 billion (yoy +6%) [5][14] Summary by Sections Equipment Bidding Trends - The bidding environment for medical equipment has been consistently high, with a diverse range of procurement preferences emerging, particularly in county-level medical communities [4][9] - The procurement scale for September 2025 indicates a strong recovery, with various equipment categories showing significant year-on-year growth [5][14] Company Performance - Leading domestic companies are aligned with industry trends, with procurement figures for September showing Mindray at 0.924 billion (yoy +6%), United Imaging at 0.804 billion (yoy +18%), and Kaili at 0.163 billion (yoy +67%) [19][22] - The focus on high-end and intelligent medical devices is expected to drive performance for leading domestic enterprises such as Mindray, United Imaging, and Kaili [6][22] Future Outlook - The ongoing equipment update policies are anticipated to positively impact the bidding market, with expectations for a new round of equipment updates to stimulate demand [22] - The approval of the "Implementation Plan for Strengthening Basic Medical and Health Services" by the State Council is expected to enhance the capabilities of grassroots medical institutions, further opening up the market [22]

Core Viewpoint - The stock of Kaili Medical has shown fluctuations in price and trading volume, with a notable increase of 19.25% year-to-date, despite a recent decline in revenue and net profit [1][2]. Financial Performance - As of June 30, 2025, Kaili Medical reported a revenue of 964 million yuan, a year-on-year decrease of 4.78%, and a net profit attributable to shareholders of 47.03 million yuan, down 72.43% compared to the previous year [2]. - The company has distributed a total of 381 million yuan in dividends since its A-share listing, with 258 million yuan distributed over the last three years [3]. Stock Market Activity - On October 16, 2023, Kaili Medical's stock price rose by 2.02%, reaching 34.93 yuan per share, with a total market capitalization of 15.115 billion yuan [1]. - The stock has experienced a trading volume of 57.6415 million yuan, with a turnover rate of 0.39% [1]. - The main capital flow indicated a net outflow of 2.5509 million yuan, with significant buying and selling activity from large orders [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased to 14,300, while the average circulating shares per person increased by 1.48% to 30,244 shares [2]. - Notable institutional shareholders include Huabao Zhongzheng Medical ETF and Guangfa Medical Health Stock A, with both increasing their holdings [3].

证券之星消息，截至2025年10月15日收盘，开立医疗(300633)报收于34.24元，上涨2.24%，换手率 1.17%，成交量5.04万手，成交额1.71亿元。 10月15日的资金流向数据方面，主力资金净流入513.26万元，占总成交额3.0%，游资资金净流出123.7 万元，占总成交额0.72%，散户资金净流出389.56万元，占总成交额2.28%。 近5日资金流向一览见下表： 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 | 指标 | 开立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 148.16亿元 | 118.79亿元 | 21 123 | | 净资产 | 31.16亿元 | 38.89亿元 | 47 123 | | 净利润 | 4703.03万元 | 1.49亿元 | 60 123 | | 市盈率(动) | 157.52 | 67.67 | 81 123 | | 市净率 | 4.76 | 3.82 | 96 123 | | 毛利率 | 62.08% | 51.85% | 50 ...

Core Viewpoint - The stock of Kaili Medical has shown fluctuations in trading performance, with a recent increase of 2.00% and a year-to-date rise of 16.62%, despite a decline in revenue and net profit for the first half of 2025 [1][2]. Financial Performance - As of June 30, 2025, Kaili Medical reported a revenue of 964 million yuan, a year-on-year decrease of 4.78%, and a net profit attributable to shareholders of 47.03 million yuan, down 72.43% compared to the previous year [2]. - The company has distributed a total of 381 million yuan in dividends since its A-share listing, with 258 million yuan distributed over the last three years [3]. Shareholder Information - The number of shareholders for Kaili Medical decreased by 1.46% to 14,300 as of June 30, 2025, while the average number of circulating shares per person increased by 1.48% to 30,244 shares [2]. - Major shareholders include Hua Bao Zhong Zheng Medical ETF, which increased its holdings by 134,200 shares, and Guangfa Medical Care Stock A, which increased its holdings by 836,200 shares [3]. Stock Performance - The stock price of Kaili Medical is currently at 34.16 yuan per share, with a market capitalization of 14.781 billion yuan. The stock has experienced a 0.64% decline over the past five trading days and a 5.71% decline over the past 20 days, while it has increased by 20.83% over the past 60 days [1].

| 指标 | 开立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 144.92亿元 | 117.95亿元 | 21 123 | | 净资产 | 31.16亿元 | 38.89亿元 | 47 123 | | 净利润 | 4703.03万元 | 1.49亿元 | 60 123 | | 市盈率(动) | 154.07 | 66.45 | 81 123 | | 市净率 | 4.65 | 3.78 | 96 123 | | 毛利率 | 62.08% | 51.85% | 50 123 | | 净利率 | 4.88% | 10.39% | 84 123 | | ROE | 1.5% | 1.8% | 75 123 | 证券之星消息，截至2025年10月14日收盘，开立医疗(300633)报收于33.49元，下跌1.82%，换手率 0.84%，成交量3.65万手，成交额1.23亿元。 10月14日的资金流向数据方面，主力资金净流出236.31万元，占总成交额1.91%，游资资金净流入 294.81万元，占总成交额2.39%，散户资金净流出58.49万元，占总 ...

Investment Rating - The report maintains a "Market Weight" rating for the pharmaceutical and biotechnology industry [2][24]. Core Viewpoints - The SW pharmaceutical and biotechnology industry underperformed the Shanghai and Shenzhen 300 index, declining by 0.23% from September 26, 2025, to October 9, 2025, lagging behind the index by approximately 2.76 percentage points [9][24]. - Most sub-sectors within the industry recorded negative returns during the same period, with the medical research outsourcing and in vitro diagnostics sectors showing gains of 1.99% and 0.55%, respectively, while the raw materials and chemical preparations sectors fell by 2.23% and 1.73% [10][24]. - Approximately 54% of stocks in the industry achieved positive returns, with the top performer, Zhendemedical, increasing by 21.43%, while the largest decline was seen in Guangshentang, which fell by 21.86% [11][14]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 55.04 times as of October 9, 2025, indicating a decrease in industry valuation [15][24]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the Shanghai and Shenzhen 300 index, with a decline of 0.23% from September 26, 2025, to October 9, 2025 [9]. - Most sub-sectors recorded negative returns, with medical research outsourcing and in vitro diagnostics performing better than others [10]. - About 54% of stocks in the industry recorded positive returns, with significant variations in individual stock performance [11]. 2. Industry News - The 11th batch of national procurement will begin accepting applications on October 21, 2025, with 55 major varieties included [22]. - The National Medical Products Administration issued guidelines for the quality management of medical device online sales [20][21]. 3. Company Announcements - Zhejiang Haizheng Pharmaceutical announced that its product achieved Self-GRAS certification in the U.S., allowing it to enter the U.S. market [23]. 4. Weekly Industry Perspective - The report suggests focusing on investment opportunities in innovative drugs and sectors with expected business development catalysts, including medical devices and pharmaceutical commerce [24][26].

Core Viewpoint - KAILI Medical's stock price has shown fluctuations, with a year-to-date increase of 15.02%, but a recent decline of 3.49% over the last five trading days, indicating potential volatility in the market [1] Financial Performance - For the first half of 2025, KAILI Medical reported a revenue of 964 million yuan, a year-on-year decrease of 4.78%, and a net profit attributable to shareholders of 47.03 million yuan, down 72.43% compared to the previous year [2] - Cumulative cash dividends since the A-share listing amount to 381 million yuan, with 258 million yuan distributed over the last three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 1.46% to 14,300, while the average circulating shares per person increased by 1.48% to 30,244 shares [2] - Notable institutional shareholders include Huabao Zhongzheng Medical ETF and Guangfa Medical Health Stock A, with both increasing their holdings [3] Company Overview - KAILI Medical, established on September 27, 2002, and listed on April 6, 2017, specializes in the research, development, production, and sales of medical diagnostic and treatment equipment [1] - The company's main revenue sources are color ultrasound (58.07%) and endoscopes and related therapeutic instruments (40.90%) [1] Market Position - KAILI Medical operates within the pharmaceutical and biological industry, specifically in the medical device sector, and is involved in various concept sectors including medical devices and in vitro diagnostics [1]